Major histocompatibility complex class II-T-cell receptor-CD4 complex (MHC II-TCR-CD4 complex)

The Major histocompatibility complex class II-T-cell receptor-CD4 complex (MHC II-TCR-CD4) is a multi-protein assembly that serves as the primary bridge between innate and adaptive immunity. It forms when an antigen-presenting cell (APC) displays an exogenous peptide on an MHC class II molecule, which is then recognized by a specific T-cell receptor (TCR) on a CD4+ T helper cell [1]. The CD4 molecule acts as a critical co-receptor, binding to the invariant region of the MHC II molecule to stabilize the interaction and recruit the kinase Lck to the TCR complex, initiating intracellular signaling [2]. This interaction constitutes the Signal 1 required for T-cell activation, leading to the proliferation and differentiation of T helper subsets that coordinate immune responses against pathogens [3]. In autoimmune diseases, this complex inappropriately recognizes self-antigens, leading to tissue destruction, while in cancer, its activity may be suppressed to allow tumor evasion [4]. Pharmacological modulation of this complex includes the use of monoclonal antibodies to block CD4 or the TCR, as well as peptide analogs that compete for MHC II binding, providing a pathway to treat conditions ranging from HIV infection to multiple sclerosis [5, 6]. Understanding the structural and kinetic properties of this complex is crucial for developing precision immunotherapies for chronic inflammation and cancer.

Other names

MHC class II-CD4+ T helper cell receptor complexHLA class II-TCR complexAntigen-presenting cell-T cell synapseMHC II-peptide-TCR complexImmunological synapse

Inhibition of T-cell receptor signaling, physical blockade of CD4 co-receptor binding to MHC class II, competitive inhibition of peptide loading onto MHC II molecules, and modulation of costimulatory signals within the immunological synapse [1, 5].